{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:24:07Z","timestamp":1793431447333,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7873","license":[{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2021,8,26]]},"DOI":"10.1038\/s41586-021-03744-4","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T06:04:51Z","timestamp":1625637891000},"page":"565-569","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":306,"title":["Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia"],"prefix":"10.1038","volume":"596","author":[{"given":"Angela","family":"Huynh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9418-2383","authenticated-orcid":false,"given":"John G.","family":"Kelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0943-8853","authenticated-orcid":false,"given":"Donald M.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7149-2781","authenticated-orcid":false,"given":"Mercy","family":"Daka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5695-4343","authenticated-orcid":false,"given":"Ishac","family":"Nazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,7]]},"reference":[{"key":"3744_CR1","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","volume":"384","author":"A Greinacher","year":"2021","unstructured":"Greinacher, A. et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N. Engl. J. Med. 384, 2092\u20132101 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3744_CR2","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","volume":"384","author":"NH Schultz","year":"2021","unstructured":"Schultz, N. H. et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N. Engl. J. Med. 384, 2124\u20132130 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3744_CR3","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","volume":"384","author":"M Scully","year":"2021","unstructured":"Scully, M. et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N. Engl. J. Med. 384, 2202\u20132211 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3744_CR4","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood.V72.3.925.bloodjournal723925","volume":"72","author":"JG Kelton","year":"1988","unstructured":"Kelton, J. G. et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 72, 925\u2013930 (1988).","journal-title":"Blood"},{"key":"3744_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/jth.14369","volume":"17","author":"A Huynh","year":"2019","unstructured":"Huynh, A. et al. Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin-induced thrombocytopenia. J. Thromb. Haemost. 17, 389\u2013399 (2019).","journal-title":"J. Thromb. Haemost."},{"key":"3744_CR6","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.amjmed.2008.03.012","volume":"121","author":"TE Warkentin","year":"2008","unstructured":"Warkentin, T. E., Makris, M., Jay, R. M. & Kelton, J. G. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am. J. Med. 121, 632\u2013636 (2008).","journal-title":"Am. J. Med."},{"key":"3744_CR7","doi-asserted-by":"publisher","unstructured":"Hwang, S. R. et al. Cerebral venous sinus thrombosis associated with spontaneous heparin-induced thrombocytopenia syndrome after total knee arthroplasty. Platelets https:\/\/doi.org\/10.1080\/09537104.2020.1828574 (2020).","DOI":"10.1080\/09537104.2020.1828574"},{"key":"3744_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1055\/s-0038-1651670","volume":"73","author":"J Amiral","year":"1995","unstructured":"Amiral, J. et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb. Haemost. 73, 21\u201328 (1995).","journal-title":"Thromb. Haemost."},{"key":"3744_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9277","volume":"6","author":"Z Cai","year":"2015","unstructured":"Cai, Z. et al. Atomic description of the immune complex involved in heparin-induced thrombocytopenia. Nat. Commun. 6, 8277 (2015).","journal-title":"Nat. Commun."},{"key":"3744_CR10","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1182\/blood.V84.11.3691.bloodjournal84113691","volume":"84","author":"TE Warkentin","year":"1994","unstructured":"Warkentin, T. E. et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 84, 3691\u20133699 (1994).","journal-title":"Blood"},{"key":"3744_CR11","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1182\/blood-2010-03-276964","volume":"116","author":"L Rauova","year":"2010","unstructured":"Rauova, L. et al. Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. Blood 116, 5021\u20135031 (2010).","journal-title":"Blood"},{"key":"3744_CR12","doi-asserted-by":"publisher","unstructured":"Thiele, T. et al. Frequency of positive anti-PF4\/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2. Blood https:\/\/doi.org\/10.1182\/blood.2021012217 (2021).","DOI":"10.1182\/blood.2021012217"},{"key":"3744_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1046\/j.1365-2141.1996.d01-1876.x","volume":"95","author":"P Horsewood","year":"1996","unstructured":"Horsewood, P., Warkentin, T. E., Hayward, C. P. & Kelton, J. G. The epitope specificity of heparin-induced thrombocytopenia. Br. J. Haematol. 95, 161\u2013167 (1996).","journal-title":"Br. J. Haematol."},{"key":"3744_CR14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1042\/bj3120357","volume":"312","author":"KH Mayo","year":"1995","unstructured":"Mayo, K. H. et al. Heparin binding to platelet factor-4. An NMR and site-directed mutagenesis study: arginine residues are crucial for binding. Biochem. J. 312, 357\u2013365 (1995).","journal-title":"Biochem. J."},{"key":"3744_CR15","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1055\/s-0040-1717078","volume":"121","author":"C Vayne","year":"2021","unstructured":"Vayne, C. et al. Characterization of new monoclonal PF4-specific antibodies as useful tools for studies on typical and autoimmune heparin-induced thrombocytopenia. Thromb. Haemost. 121, 322\u2013331 (2021).","journal-title":"Thromb. Haemost."},{"key":"3744_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14945","volume":"8","author":"TH Nguyen","year":"2017","unstructured":"Nguyen, T. H., Medvedev, N., Delcea, M. & Greinacher, A. Anti-platelet factor 4\/polyanion antibodies mediate a new mechanism of autoimmunity. Nat. Commun. 8, 14945 (2017).","journal-title":"Nat. Commun."},{"key":"3744_CR17","doi-asserted-by":"crossref","unstructured":"Vayne, C. et al. PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia. N. Engl. J. Med. (2021).","DOI":"10.1056\/NEJMc2106383"},{"key":"3744_CR18","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1182\/blood-2012-01-407262","volume":"120","author":"BS Sachais","year":"2012","unstructured":"Sachais, B. S. et al. Dynamic antibody-binding properties in the pathogenesis of HIT. Blood 120, 1137\u20131142 (2012).","journal-title":"Blood"},{"key":"3744_CR19","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3390\/ijms19041054","volume":"19","author":"VC Bui","year":"2018","unstructured":"Bui, V. C. & Nguyen, T. H. The role of single-molecule force spectroscopy in unraveling typical and autoimmune heparin-induced thrombocytopenia. Int. J. Mol. Sci. 19, 1054 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"3744_CR20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1538-7836.2007.02815.x","volume":"6","author":"I Socher","year":"2008","unstructured":"Socher, I., Kroll, H., Jorks, S., Santoso, S. & Sachs, U. J. Heparin-independent activation of platelets by heparin-induced thrombocytopenia antibodies: a common occurrence. J. Thromb. Haemost. 6, 197\u2013200 (2008).","journal-title":"J. Thromb. Haemost."},{"key":"3744_CR21","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/ajh.24006","volume":"90","author":"TE Warkentin","year":"2015","unstructured":"Warkentin, T. E., Arnold, D. M., Nazi, I. & Kelton, J. G. The platelet serotonin-release assay. Am. J. Hematol. 90, 564\u2013572 (2015).","journal-title":"Am. J. Hematol."},{"key":"3744_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1182\/blood-2014-06-580894","volume":"125","author":"A Padmanabhan","year":"2015","unstructured":"Padmanabhan, A. et al. Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis. Blood 125, 155\u2013161 (2015).","journal-title":"Blood"},{"key":"3744_CR23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011958","author":"A Tiede","year":"2021","unstructured":"Tiede, A. et al. Prothrombotic immune thrombocytopenia after COVID-19 vaccine. Blood https:\/\/doi.org\/10.1182\/blood.2021011958 (2021).","journal-title":"Blood"},{"key":"3744_CR24","doi-asserted-by":"publisher","unstructured":"Althaus, K. et al. Antibody-mediated procoagulant platelets in SARS-CoV-2- vaccination associated immune thrombotic thrombocytopenia. Haematologica https:\/\/doi.org\/10.3324\/haematol.2021.279000 (2021).","DOI":"10.3324\/haematol.2021.279000"},{"key":"3744_CR25","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1182\/blood.V89.2.370","volume":"89","author":"G Arepally","year":"1997","unstructured":"Arepally, G., McKenzie, S. E., Jiang, X. M., Poncz, M. & Cines, D. B. Fc\u03b3RIIA H\/R131 polymorphism, subclass-specific IgG anti-heparin\/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis. Blood 89, 370\u2013375 (1997).","journal-title":"Blood"},{"key":"3744_CR26","doi-asserted-by":"publisher","first-page":"5285","DOI":"10.1182\/blood-2011-06-359430","volume":"119","author":"RS Kasthuri","year":"2012","unstructured":"Kasthuri, R. S. et al. PF4\/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of Fc\u03b3RI. Blood 119, 5285\u20135293 (2012).","journal-title":"Blood"},{"key":"3744_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1182\/blood.V67.1.27.27","volume":"67","author":"D Sheridan","year":"1986","unstructured":"Sheridan, D., Carter, C. & Kelton, J. G. A diagnostic test for heparin-induced thrombocytopenia. Blood 67, 27\u201330 (1986).","journal-title":"Blood"},{"key":"3744_CR28","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/jth.13066","volume":"13","author":"I Nazi","year":"2015","unstructured":"Nazi, I. et al. Distinguishing between anti-platelet factor 4\/heparin antibodies that can and cannot cause heparin-induced thrombocytopenia. J. Thromb. Haemost. 13, 1900\u20131907 (2015).","journal-title":"J. Thromb. Haemost."},{"key":"3744_CR29","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/09537104.2017.1378808","volume":"29","author":"A Huynh","year":"2018","unstructured":"Huynh, A. et al. Development of a high-yield expression and purification system for platelet factor 4. Platelets 29, 249\u2013256 (2018).","journal-title":"Platelets"},{"key":"3744_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.thromres.2020.06.012","volume":"194","author":"A Huynh","year":"2020","unstructured":"Huynh, A. et al. The role of fluid-phase immune complexes in the pathogenesis of heparin-induced thrombocytopenia. Thromb. Res. 194, 135\u2013141 (2020).","journal-title":"Thromb. Res."},{"key":"3744_CR31","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/jth.15233","volume":"19","author":"JG Rubino","year":"2021","unstructured":"Rubino, J. G. et al. A comparative study of platelet factor 4-enhanced platelet activation assays for the diagnosis of heparin-induced thrombocytopenia. J. Thromb. Haemost. 19, 1096\u20131102 (2021).","journal-title":"J. Thromb. Haemost."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-021-03744-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-021-03744-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-021-03744-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T10:16:05Z","timestamp":1634724965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-021-03744-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,7]]},"references-count":31,"journal-issue":{"issue":"7873","published-print":{"date-parts":[[2021,8,26]]}},"alternative-id":["3744"],"URL":"https:\/\/doi.org\/10.1038\/s41586-021-03744-4","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740431512.793587310","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.740431512.793587609","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,7]]},"assertion":[{"value":"4 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A US provisional patent was submitted by I.N., D.M.A., J.G.K. and A.H. covering the products and methods for the diagnosis of VITT and the differentiation of VITT from HIT using the research in this study. The authors declare no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}